RERG抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P08689(RERG Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

**Background of RERG Antibody**

The **Ras-related and estrogen-regulated growth inhibitor (RERG)** is a small GTPase belonging to the Ras superfamily, initially identified as a tumor suppressor in breast cancer. Unlike classical Ras proteins, RERG lacks canonical lipid modification sites, influencing its subcellular localization and function. It is transcriptionally regulated by estrogen receptor (ER) signaling and acts as a negative regulator of cell proliferation, differentiation, and survival. RERG expression is frequently downregulated in malignancies, particularly ER-positive breast cancers, often due to promoter hypermethylation or loss of heterozygosity. This downregulation correlates with tumor progression, metastasis, and poor prognosis.

**RERG antibodies** are critical tools for detecting RERG protein expression in research and diagnostics. They enable the study of RERG's role in cancer biology, including its interplay with ER signaling, cell cycle arrest mechanisms, and interactions with pathways like MAPK/ERK. Commercial RERG antibodies are validated for techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Recent studies also explore RERG's potential as a biomarker for therapeutic response or as a target for epigenetic therapies to restore its tumor-suppressive functions. Understanding RERG dynamics through antibody-based assays contributes to insights into cancer pathogenesis and precision oncology strategies.